UNCY Share Price Performance
US$5.45
0.95 (21.11%)
74.7% undervalued intrinsic discount
US$21.53
Fair Value
Price US$5.45
stuart_roberts US$21.53
kapirey US$9.17
Fair ValueUS$21.53
Share Pricen/a
Unicycive Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 218 Fair Values set on narratives written by author
UNCY Community Narratives
ST
Fair Value
·Fair Value US$21.53 74.7% undervalued intrinsic discount
Looking to be second time lucky with a game-changing new product
21users have liked this narrative
0users have commented on this narrative
162users have followed this narrative
KA
Fair Value
·Fair Value US$9.17 40.6% undervalued intrinsic discount
Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Looking to be second time lucky with a game-changing new product
Unicycive’s kidney drug aims to make life easier for dialysis patients by cutting down the daily pill burden, and it could finally reach the market after a manufacturing setback. The next big moment is the regulator’s decision, but the same manufacturing and rollout risks still hang over the story.Read more
ST
US$21.53
74.7% undervalued intrinsic discount
Fair Value
Profit Margin
20%
Future PE
27x
Price in 2030
US$34.67
Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
A small kidney-disease drug developer is nearing a make-or-break decision that could turn it from a research story into a company with real product sales. The big question is whether it can clear past manufacturing hurdles and win over dialysis clinics that are slow to change and tightly controlled by insurers.Read more
Trending Discussion
No trending discussion available.
Recently Updated Narratives
KA
Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
Fair Value: US$9.17 40.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Unicycive Therapeutics, Inc. Key Details
About UNCY
- Founded
- 2016
- Employees
- 22
- CEO
- WebsiteView website
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
